We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
(+14%)
Cap. Flow
+$849M
Cap. Flow
% of AUM
5.76%
Top 10 Holdings %
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$128M |
| 2 |
Intel
INTC
|
+$88.4M |
| 3 |
Prudential Financial
PRU
|
+$72.7M |
| 4 |
Lam Research
LRCX
|
+$62.6M |
| 5 |
SBA Communications
SBAC
|
+$58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$98.3M |
| 2 |
Target
TGT
|
+$86.8M |
| 3 |
Occidental Petroleum
OXY
|
+$74.7M |
| 4 |
Synchrony
SYF
|
+$61.6M |
| 5 |
Intercontinental Exchange
ICE
|
+$57.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 13.54% |
| 3 | Financials | 13.08% |
| 4 | Consumer Discretionary | 12.97% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
HBT Financial
HBT
$1.26B
| $943K | 0.01% |
54,136
-13,029
| -19% | -$231K |
|
|
NTST
752
NETSTREIT Corp
NTST
$2.16B
| $942K | 0.01% |
40,870
-59,712
| -59% | -$1.3M |
|
753
Texas Roadhouse
TXRH
$13.2B
| $941K | 0.01% |
+9,778
| New | +$962K |
|
754
Valhi
VHI
$382M
| $921K | 0.01% |
37,849
+14,254
| +60% | +$369K |
|
755
Carter Bankshares
CARE
$760M
| $917K | 0.01% |
73,280
+3,922
| +6% | +$54.8K |
|
756
Noodles & Co
NDLS
$87.7M
| $912K | 0.01% |
9,137
-369
| -4% | -$34.3K |
|
757
4D Molecular Therapeutics
FDMT
$542M
| $901K | 0.01% |
+37,417
| New | +$1.15M |
|
|
DHC
758
Diversified Healthcare Trust
DHC
$2.25B
| $900K | 0.01% |
215,358
+103,389
| +92% | +$427K |
|
|
INBX
759
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $899K | 0.01% |
32,664
+2,243
| +7% | +$46.7K |
|
|
CDTX
760
DELISTED
Cidara Therapeutics
CDTX
| $891K | 0.01% |
22,053
-11,710
| -35% | -$495K |
|
761
Regional Management Corp
RM
$387M
| $888K | 0.01% |
19,091
+3,340
| +21% | +$145K |
|
762
C4 Therapeutics
CCCC
$401M
| $886K | 0.01% |
+23,413
| New | +$839K |
|
763
Piper Sandler
PIPR
$5.14B
| $881K | 0.01% |
27,196
-39,660
| -59% | -$1.21M |
|
764
Radiant Logistics
RLGT
$414M
| $879K | 0.01% |
126,782
+18,043
| +17% | +$131K |
|
|
SYNH
765
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $876K | 0.01% |
+9,786
| New | +$827K |
|
766
Meridian
MRBK
$237M
| $870K | 0.01% |
66,322
-4,802
| -7% | -$63.1K |
|
767
Spok Holdings
SPOK
$226M
| $864K | 0.01% |
89,794
| – | – |
|
|
JNCE
768
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $863K | 0.01% |
126,857
-1,128
| -0.9% | -$9.37K |
|
769
Assembly Biosciences
ASMB
$520M
| $856K | 0.01% |
18,375
-3,035
| -14% | -$150K |
|
770
Johnson & Johnson
JNJ
$646B
| $854K | 0.01% |
5,181
+2,432
| +88% | +$403K |
|
|
SIC
771
DELISTED
Select Interior Concepts, Inc. Class A Common Stock
SIC
| $853K | 0.01% |
+90,767
| New | +$853K |
|
772
LSI Industries
LYTS
$841M
| $852K | 0.01% |
106,386
-30,681
| -22% | -$258K |
|
|
SCPH
773
DELISTED
scPharmaceuticals
SCPH
| $847K | 0.01% |
138,604
-2,363
| -2% | -$14.3K |
|
774
Sinclair Inc
SBGI
$1B
| $840K | 0.01% |
+25,285
| New | +$818K |
|
775
Karyopharm Therapeutics
KPTI
$164M
| $839K | 0.01% |
+5,417
| New | +$786K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q2 2021 Portfolio in Review
As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.
- Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
- Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
- Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
- Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
- Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
- Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.